Quantum BioPharma Ltd. QNTM
Set alert
As of Nov 3, 1:01 PM ET
- YTD
- -68.97%
- 1 year
- -78.47%
- Open
- 2.34
- Prev close
- 2.25
- Mkt cap
- 14.56M
- Vol
- 20.43K
- Avg vol
- 211.69K
- EPS
- -4.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.24
- High
- 2.34
- Forward P/E
- -0.41
- Beta
- 0.00
- Short ratio
- 0.09
- Inst. own
- 16.65%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.92
- 200-d avg
- 14.62
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 11, 2024Earnings: -4.37; estimate -2.78; surprise -57.19%
Signals (80)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 4 days ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 4 weeks ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Sell Signal | May 29, 2026 | 5 months ago |
| RSI: Overbought | May 20, 2026 | 5 months ago |
| RSI: Overbought | May 14, 2026 | 5 months ago |
Newest 20 of 80.
Key statistics
- Market cap
- 6.16M
- Enterprise value
- -4.42M
- Trailing P/E
- 0.00
- Forward P/E
- -0.41
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.18
- EPS (TTM)
- -13.19
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -9.24M
- Total cash
- 6.61M
- Total debt
- 373.02K
- Return on equity
- -73.84%
- Shares outstanding
- 1.92M
- Short % of float
- 0.33%
- 50-day average
- 4.92
- 200-day average
- 14.62
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -2.78 | -4.37 | -1.59 | -57.19% |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- quantumbiopharma.com
News
- Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings
- World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
- Thermo Fisher Scientific (NYSE:TMO) Sets New 52-Week High – Time to Buy?
- Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
- EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
- Quantum BioPharma’s Licensee Unbuzzd Wellness Announces Appointment Of Michael Zapolin As CEO
- Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
- Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
- Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Your note
Sign in to keep a note on QNTM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 1.37% | 26,233 | 84.21K | Sep 29, 2024 |
| Virtu Financial LLC | 0.60% | 11,428 | 36.68K | Sep 29, 2024 |
| HRT Financial LP | 0.52% | 10,041 | 32.23K | Sep 29, 2024 |
| Royal Bank of Canada | 0.01% | 107 | 343 | Sep 29, 2024 |
| Group One Trading, L.P. | 0.01% | 172 | 552 | Sep 29, 2024 |
| National Bank of Canada/FI | 0.00% | 48 | 154 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 3.69% | 70,898 | 227.58K | Oct 30, 2024 |